Cannabis Shows Behavioral Benefits in Dementia Patients, New Study Finds

Study Design and Patient Outcomes

The 12-week randomized trial enrolled 84 nursing-home residents with moderate to severe dementia across six facilities in Colorado and Oregon. Participants received either a 2.5mg THC / 2.5mg CBD oral capsule twice daily or placebo. Researchers measured change in Cohen-Mansfield Agitation Inventory (CMAI) scores at week 12 as the primary endpoint.

The treatment group showed a mean 7.2-point reduction in CMAI scores compared to 2.1 points in the placebo arm, according to lead investigator Dr. Elena Martínez of the University of Colorado Anschutz Medical Campus. That difference cleared the pre-specified threshold for clinical significance. Secondary measures included caregiver burden, sleep duration via actigraphy, and appetite.

Sleep duration increased by an average 42 minutes per night in the cannabinoid group versus 11 minutes for placebo. Not a single patient discontinued treatment due to adverse events. Sedation rates were comparable between arms. The study excluded patients with active substance-use disorders or contraindications to cannabinoids.

Mechanism and Terpene Profile Considerations

The formulation used a 1:1 THC:CBD ratio with added beta-caryophyllene at 15mg per dose, targeting CB2 receptor pathways implicated in neuroinflammation. Beta-caryophyllene is a sesquiterpene that selectively binds CB2 receptors without psychoactivity, a profile the research team selected to minimize cognitive side effects in a vulnerable population.

Dr. Martínez said prior dementia trials using THC-only formulations reported higher dropout rates due to confusion or dizziness. The addition of CBD and beta-caryophyllene appeared to modulate those effects. A licensed Colorado processor manufactured the capsules under Good Manufacturing Practice protocols, with batch-to-batch cannabinoid variance held below 5%.

Terpene content was verified via gas chromatography-mass spectrometry. The beta-caryophyllene dose was roughly triple the amount found in a typical 100mg serving of a high-caryophyllene cultivar like GSC or Bubba Kush, suggesting therapeutic levels require concentrated isolates rather than whole-flower products.

Clinical and Regulatory Implications

The findings arrive as the DEA's proposed rescheduling of cannabis to Schedule III enters its final comment period, with geriatric-care advocates citing dementia as a high-unmet-need indication. Currently no FDA-approved pharmacologic treatments exist for agitation in dementia. Antipsychotics carry black-box warnings for increased mortality in this population.

A $2.1 million grant from the National Institute on Aging funded the study. Dr. Martínez said her team is preparing a Phase III protocol targeting 300 patients across 15 sites, pending FDA clearance under an Investigational New Drug application. If that trial replicates the Phase II results, the sponsor—a university spinout called NeuroPhyte Therapeutics—would file a New Drug Application by 2029.

For context on the evolving federal research landscape, see the CannIntel topic hub on cannabis and dementia research. State medical-cannabis programs in 38 states already list dementia or Alzheimer's disease as qualifying conditions, though evidence to date has been mostly anecdotal or drawn from retrospective chart reviews.

Limitations include the nursing-home setting, which may not generalize to community-dwelling patients, and the exclusion of patients on concurrent antipsychotics. The research team also didn't assess long-term safety beyond 12 weeks or measure cognitive outcomes, focusing instead on behavioral symptoms and caregiver quality of life.

We'll be watching for FDA clearance of the Phase III protocol and whether NeuroPhyte can replicate these results at scale across a more diverse patient population by 2027.